Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PPI Clear all
Not yet recruiting Phase 2 Interventional

Oral Fosamprenavir + Sodium Alginate for GERD

NCT06704100
View directory record Official record
Conditions
Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease
Interventions
Fosamprenavir Calcium & Sodium Alginate, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 5, 2026, 10:58 AM EDT
Withdrawn Not applicable Interventional

PPI Versus Placebo in Severe Functional Heartburn

NCT00222989
View directory record Official record
Conditions
GERD
Interventions
PPI
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2100
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

NCT03849690
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906, Esomeprazole
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 5, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT05996627
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil, Biospecimen Collection, Electronic Health Record Review, Placebo Administration
Drug · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Duarte, California • Tampa, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 5, 2026, 10:58 AM EDT
Recruiting No phase listed Observational

Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study

NCT03312686
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
endoflip
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC

NCT00746733
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lisdexamfetamine Dimesylate, Adderall XR (mixed salts amphetamine)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

NCT00573924
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage
Interventions
Proton pump inhibitor (lansoprazole)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Proton Pump Inhibitors on Endothelial Function

NCT02022280
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Lansoprazole, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)

NCT06619314
View directory record Official record
Conditions
Healthy
Interventions
Calderasib, PPI
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 5, 2026, 10:58 AM EDT
Withdrawn Not applicable Interventional

Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)

NCT02039869
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Non Erosive Reflux Disease, Dyspepsia
Interventions
Confocal endomicroscopy, Proton pump inhibitor, Sucralfate
Device · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Kenner, Louisiana • Charleston, South Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 5, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

NCT05517928
View directory record Official record
Conditions
Healthy
Interventions
Omeprazole, Lactobacillus rhamnosus GG, Placebo
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 5, 2026, 10:58 AM EDT
Terminated No phase listed Observational

Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)

NCT02769637
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
PPI treatment
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

NCT04488016
View directory record Official record
Conditions
Bioavailability, B-cell Lymphoid Cancer
Interventions
Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Symptom Control Satisfaction With Proton Pump Inhibitor Regimen

NCT02623816
View directory record Official record
Conditions
Heartburn
Interventions
Optimal Dosing of Omeprazole
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

NCT01980095
View directory record Official record
Conditions
Dyspepsia, Helicobacter Pylori Infection
Interventions
RHB-105, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Anaheim, California • Chino, California • Jupiter, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 5, 2026, 10:58 AM EDT
Terminated Phase 1 Interventional

Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors

NCT00100347
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma,, Solid Tumors
Interventions
PPI-2458
Drug
Lead sponsor
PRAECIS Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2007 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers

NCT04984525
View directory record Official record
Conditions
Healthy
Interventions
SYNB1934, SYNB1618
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 5, 2026, 10:58 AM EDT
Not listed No phase listed Observational

Management of Esophagitis Following Repair of Esophageal Atresia

NCT03619408
View directory record Official record
Conditions
Esophageal Atresia, Esophagitis
Interventions
Antacids
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 17 Years
Enrollment
50 participants
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Not applicable Interventional Results available

Proton Pump Inhibitors and Dysbiosis in Cirrhosis

NCT01458990
View directory record Official record
Conditions
Cirrhosis, Healthy
Interventions
Omeprazole
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gastric pH and Anthocyanin Absorption

NCT01122160
View directory record Official record
Conditions
Anthocyanin Metabolism
Interventions
omeprazole, placebo
Drug
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
22 Years to 59 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 Food Effect and Proton Pump Inhibitor Study

NCT05571787
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
HMPL-523, Rabeprazole
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 5, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT07116031
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619
View directory record Official record
Conditions
Healthy
Interventions
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 5, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sensorimotor Gating in Schizophrenia

NCT00561561
View directory record Official record
Conditions
Schizophrenia
Interventions
Acoustic startle testing
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
531 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2011
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 5, 2026, 10:58 AM EDT